Leerink Partners Downgrades Regeneron Pharma (REGN) to Market Perform, 'on LAG-3 Failure and Eylea Erosion Risk'
Leerink Partners analyst Andrew Berens downgraded Regeneron Pharma (NASDAQ: REGN) from ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
